Aspergillus Mold Allergy: ABPA, 30 Allergens, and 2024 Diagnostic Criteria

Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease caused by an exaggerated immune response to Aspergillus fumigatus colonizing the bronchial airways. It occurs exclusively in patients with pre-existing asthma (prevalence approximately 11.3% of asthmatics) or cystic fibrosis (7–13%). The condition is not simply an 'allergy attack' — it involves ongoing Aspergillus bronchial colonization driving eosinophilic airway inflammation, mucus plug formation, and if untreated, progressive bronchiectasis and pulmonary fibrosis. The 2024 ISHAM diagnostic criteria require a predisposing condition (asthma/CF), Aspergillus-specific IgE ≥0.35 kUA/L, total serum IgE ≥500 IU/mL, and at least two of: elevated Aspergillus IgG, eosinophils ≥500 cells/µL, or characteristic CT findings.

Aspergillus mold allergy and ABPA are immune-mediated conditions affecting patients with intact — even overactive — immune responses, primarily those with atopic asthma. The problem is too much immune response, not too little. Invasive aspergillosis is the opposite: it occurs in patients with severely impaired immunity (neutropenia, organ transplant, HSCT) who cannot eliminate inhaled conidia. Invasive aspergillosis carries 25–90% mortality and requires emergency systemic antifungal treatment with voriconazole. Allergic patients do not develop invasive aspergillosis unless they become immunocompromised for an independent reason. These conditions share the same organism but occupy opposite ends of the immune response spectrum.

The 2024 ISHAM revised ABPA criteria lowered the required total serum IgE threshold from 1000 IU/mL (the prior standard) to 500 IU/mL. This change improved diagnostic sensitivity from 91% to 98%, meaning significantly fewer ABPA cases will be missed. The 2024 criteria require: (1) a predisposing condition (asthma or cystic fibrosis), (2) Aspergillus fumigatus-specific IgE ≥0.35 kUA/L, and (3) total serum IgE ≥500 IU/mL. Additionally, ≥2 of the following are required: elevated Aspergillus-specific IgG, blood eosinophils ≥500 cells/µL, or characteristic CT imaging findings. High-attenuation mucus (HAM) on CT is pathognomonic — confirming ABPA independently regardless of other criteria.

Allergen immunotherapy (allergy shots or sublingual drops) is NOT recommended for Aspergillus sensitization or ABPA by international guidelines. Unlike Alternaria — where multiple DBPC-RCTs validate immunotherapy — Aspergillus AIT has very limited evidence and carries the theoretical risk of triggering inflammatory exacerbations in patients with active bronchial colonization. ABPA management uses a different therapeutic paradigm: oral corticosteroids and itraconazole to reduce inflammation and fungal load, and biologics (omalizumab, anti-IL5 agents) for refractory disease. Concurrent non-Aspergillus allergen sensitivities (dust mites, grass, Alternaria) CAN be treated with immunotherapy to reduce overall allergic burden without the risks of Aspergillus-specific AIT.

These are the most clinically important Aspergillus allergen components for diagnostic precision. Asp f 1 is an 18 kDa ribotoxin that is species-specific for A. fumigatus (unlike cross-reactive proteins shared with Penicillium) and detects genuine sensitization with 80% sensitivity for ABPA. Asp f 3 is a peroxisomal protein with 93.3% sensitivity in cystic fibrosis patients. Asp f 4 and Asp f 6 together achieve 99.2% specificity for distinguishing ABPA from simple Aspergillus sensitization — the highest precision available for any mold diagnostic combination. Clinically, testing rAsp f 1 or f3 (for sensitization confirmation) plus rAsp f 4 or f6 (for ABPA diagnosis) is the optimal component panel for evaluating an asthmatic patient with elevated total IgE and Aspergillus-specific IgE.

Aspergillus conidia are found in virtually all environments worldwide — indoors and outdoors. The average person inhales several hundred A. fumigatus conidia daily without consequence because a healthy immune system eliminates them efficiently. Indoor Aspergillus is particularly concentrated in HVAC systems, potted plant soil, humidifiers, compost, and damp building materials. Maintaining indoor humidity below 50%, replacing HVAC filters regularly, and avoiding potting soil in sleeping areas reduces indoor spore loads. For immunocompromised individuals, HEPA-filtered positive-pressure environments with ≥12 air changes per hour are used in healthcare settings to minimize exposure. Complete Aspergillus elimination from ordinary living environments is neither achievable nor necessary for most allergic patients.

High-attenuation mucus (HAM) is a CT scan finding in ABPA in which mucus plugs within bronchi appear brighter (denser) than skeletal muscle on imaging. This occurs because eosinophils, hyphal elements, and calcium deposits make ABPA mucus plugs physically denser than ordinary mucus. HAM is considered pathognomonic for ABPA — meaning its presence on CT confirms the diagnosis independently, without requiring additional criteria to be met. HAM corresponds to the ABPA-HAM staging category in the 2024 ISHAM classification and indicates more advanced disease than simple seropositive ABPA (ABPA-S) or ABPA with bronchiectasis only (ABPA-B). Identifying HAM early allows more aggressive treatment to prevent progression to chronic pleuropulmonary fibrosis.

Yes — ABPA occurs in children with asthma and cystic fibrosis, though the diagnosis can be more challenging to establish in pediatric populations where normal IgE ranges differ and symptoms may overlap with other common pediatric respiratory conditions. The 2024 ISHAM criteria apply to adults; pediatric ABPA diagnostic criteria require adaptation for age-appropriate IgE thresholds and spirometry interpretation. Cystic fibrosis patients face a 7–13% ABPA prevalence across all ages and require systematic Aspergillus sensitization monitoring as part of CF care. Pediatric allergists and pulmonologists with CF experience are best positioned to evaluate children for ABPA and guide treatment that minimizes cumulative corticosteroid exposure during growth-critical years.

Omalizumab (Xolair) is an anti-IgE monoclonal antibody approved for severe allergic asthma that has emerged as the most studied biologic for refractory ABPA. It works by binding free IgE, reducing its availability to bind to mast cells and basophils — thereby reducing the IgE-driven inflammation at the core of ABPA pathophysiology. Multiple case series and prospective studies consistently show that omalizumab significantly reduces ABPA exacerbation frequency, lowers total IgE levels, decreases the required oral corticosteroid dose, and improves quality of life in patients with difficult-to-control ABPA. It is particularly valuable in patients who have experienced serious steroid complications (osteoporosis, diabetes) from repeated prednisolone courses. Anti-IL5 biologics (mepolizumab, benralizumab) target eosinophils and have shown complementary benefit in reducing mucus plugging.